Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Respiratory Medicine

Volumn 107, Issue 11, 2013, Pages 1709-1721

  Nielsen, Rune ^a,b   Kankaanranta, Hannu ^c   Bjermer, Leif ^d   Lange, Peter ^e   Arnetorp, Sofie ^f   Hedegaard, Morten ^f   Stenling, Anna ^f   Mittmann, Nicole ^g  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f ASTRAZENECA R AND D   (Sweden)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

Budesonide formoterol; COPD; Cost effectiveness; Nordic; Tiotropium

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; GLUCOCORTICOID; HANDIHALER; PLACEBO; TERBUTALINE; TIOTROPIUM BROMIDE; TURBUHALER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BOOTSTRAPPING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENMARK; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FINLAND; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NORWAY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SWEDEN;

BUDESONIDE/FORMOTEROL; COPD; COST EFFECTIVENESS; NORDIC; TIOTROPIUM;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; BRONCHODILATOR AGENTS; BUDESONIDE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG COSTS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; GLUCOCORTICOIDS; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCANDINAVIA; SCOPOLAMINE DERIVATIVES; SICK LEAVE; TREATMENT OUTCOME;

EID: 84887099441     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.06.007     Document Type: Article

References (61)

1. P. Fabricius, A. Lokke, J.L. Marott, J. Vestbo, and P. Lange Prevalence of COPD in Copenhagen Respir Med 105 2011 410 417
2. J.G. Hansen, L. Pedersen, K. Overvad, O. Omland, H.K. Jensen, and H.T. Sørensen The prevalence of chronic obstructive pulmonary disease among danes aged 45-84 years: population-based study COPD 5 2008 347 352
3. V.L. Kinnula, T. Vasankari, E. Kontula, A. Sovijarvi, O. Saynajakangas, and A. Pietinalho The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality Prim Care Respir J 20 2011 178 183
4. J.-T. Kotaniemi, A. Sovijärvi, and B. Lundbäck Chronic obstructive pulmonary disease in Finland: prevalence and risk factors COPD 2 2005 331 339
5. S.C. Hvidsten, L. Storesund, T. Wentzel-Larsen, A. Gulsvik, and S. Lehmann Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general population Clin Respir J 4 2010 13 21
6. A. Johannessen, E.R. Omenaas, P.S. Bakke, and A. Gulsvik Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study Thorax 60 2005 842 847
7. A. Lindberg, A. Bjerg, E. Ronmark, L.G. Larsson, and B. Lundback Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking report from the obstructive lung disease in Northern Sweden Studies Respir Med 100 2006 264 272
8. B. Lundback, A. Lindberg, M. Lindstrom, E. Ronmark, A.C. Jonsson, and E. Jonsson Not 15 but 50% of smokers develop COPD?-Report from the obstructive lung disease in Northern Sweden Studies Respir Med 97 2003 115 122
9. A.S. Buist, M.A. McBurnie, W.M. Vollmer, S. Gillespie, P. Burney, and D.M. Mannino International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study Lancet 370 2007 741 750
10. L.K. Tynkkynen, T. Klaukka, A. Pietinalho, and P. Rissanen The costs of COPD in Finland in 2006 Finnish Med J 64 2009 2095 2099
11. S.A. Jansson, F. Andersson, S. Borg, A. Ericsson, E. Jonsson, and B. Lundback Costs of COPD in Sweden according to disease severity Chest 122 2002 1994 2002
12. F. Andersson, S. Borg, S.A. Jansson, A.C. Jonsson, A. Ericsson, and C. Prutz The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med 96 2002 700 708
13. L. Bilde, A. Rud Svenning, J. Dollerup, H. Baekke Borgeskov, and P. Lange The cost of treating patients with COPD in Denmark-a population study of COPD patients compared with non-COPD controls Respir Med 101 2007 539 546
14. R. Nielsen, A. Johannessen, B. Benediktsdottir, T. Gislason, A.S. Buist, and A. Gulsvik Present and future costs of COPD in Iceland and Norway: results from the BOLD study Eur Respir J 34 2009 850 857
15. B.R. Celli, N.E. Thomas, J.A. Anderson, G.T. Ferguson, C.R. Jenkins, and P.W. Jones Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
16. T.A. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, and J.A. Wedzicha Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 1418 1422
17. D.C. Suh, H. Lau, H.O. La, I.S. Choi, and G.P. Geba Association between incidence of acute exacerbation and medication therapy in patients with COPD Curr Med Res Opin 26 2010 297 306
18. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Updated 2010 At: http://www.goldcopd.org/ [accessed May 2011]
19. National Institute for Health and Clinical Excellence Chronic obstructive pulmonary disease (Clinical guideline 12) Updated February 2004 At: http://www.nice.org.uk/nicemedia/pdf/CG012-niceguideline.pdf [accessed May 2011]
20. T. Welte, M. Miravitlles, P. Hernandez, G. Eriksson, S. Peterson, and T. Polanowski Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 741 750
21. M. Najafzadeh, C.A. Marra, M. Sadatsafavi, S.D. Aaron, S.D. Sullivan, and K.L. Vandemheen Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD Thorax 63 2008 962 967
22. J.B. Oostenbrink, M.P. Rutten-van Molken, M.J. Al, J.A. Van Noord, and W. Vincken One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Eur Respir J 23 2004 241 249
23. M.P. Rutten-van Molken, F.E. van Nooten, M. Lindemann, M. Caeser, and P.M. Calverley A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease Pharmacoeconomics 25 2007 695 711
24. N. Mittmann, P. Hernandez, C. Mellstrom, L. Brannman, and T. Welte Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives Pharmacoeconomics 29 2011 403 414
25. A. Alban, M. Gyldmark, A.V. Pedersen, and J. Sogaard The Danish approach to standards for economic evaluation methodologies Pharmacoeconomics 12 1997 627 636
26. Decree of the Ministry of Social Affairs and Health on applications and price notifications made to the Pharmaceuticals Pricing Board (201/2009) - appendix: guidelines for preparing a health economic evaluation (360/2011). At: http://www.finlex.fi/ [accessed May 2011].
27. Norwegian Medicines Agency Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement Updated 13 October 2005 At: http://www.legemiddelverket.no/templates/InterPage-25644.aspx [accessed May 2011]
28. The Dental and Pharmaceutical Benefits Agency General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) Updated 24 April 2003 At: http://www.tlv.se/Upload/English/ENG-lfnar-2003-2.pdf [accessed May 2011]
29. Dansk Lægemiddel Information Diagnostik og stadieinddeling af KOL Updated 2010 At: http://pro.medicin.dk/Laegemiddelgrupper/Grupper/315302 [accessed May 2011]
30. K. Stavem, G. Bjerke, F.N. Kjelsberg, E.A. Ruud, and S.O. Saxrud Den norske lægeforenings strategigruppe for KOLS. Veileder til diagnose, behandling och forebygging av kronisk obstruktiv lungesykdom (KOLS) Tidsskr Nor Lægeforen 122 2002 2290 2293
31. Läkemedelsverket. Farmakologisk behandling av kroniskt obstruktiv lungsjukdom (KOL) - ny rekommendation Inf FrånLäkemedelsverket 20 2009 13 81
32. Working group set up by the Finnish medical society Duodecim and the Finnish Respiratory society 2009 Finnish Medical Society Duodecim Helsinki (referred 16 June 2009). At: http://www.kaypahoito.fi/ [accessed May 2011]
33. Danish Medicines Agency. Medicinpriser. At: http://www.medicinpriser.dk/ [accessed April 2011].
34. Ministry of Social Affairs and Health. At: http://www.stm.fi/ [accessed March 2011].
35. Norwegian Medicines Agency. At: http://www.legemiddelverket.no/ [accessed March 2011].
36. The Dental and Pharmaceutical Benefits Agency. At: http://www.tlv.se/ [accessed March 2011].
37. The Nordic Social-Statistical Committee Old-age pension systems in the Nordic countries Updated 2008 At: http://nososco-eng.nom-nos.dk/2008 [accessed April 2011]
38. C.G. Lofdahl, B. Tilling, T. Ekstrom, L. Jorgensen, G. Johansson, and K. Larsson COPD health care in Sweden - A study in primary and secondary care Respir Med 104 2010 404 411
39. Organisation for Economic Co-operation and Development (OECD). Unit Labour Costs - Annual Indicators (ULC-ANN). Labour Compensation per Employee. At: http://stats.oecd.org/ [accessed June 2011].
40. Statistics Finland. Price index of public expenditure, municipal finances 2005=100, healthcare. At: http://www.stat.fi/ [accessed June 2011].
41. Statistics Finland. Price index of public expenditure, municipal finances, old indexes, 2000=100, healthcare. At: http://www.stat.fi/ [accessed June 2011].
42. Statistics Norway. Consumer Price Index (Health and All items), 1998=100. Updated 2011. At: http://www.ssb.no/ [accessed April 2011].
43. National Institute for health and Welfare Finland 2010 At: http://www.thl.fi [accessed May 2011]
44. The Swedish Association of Local Authorities and Regions. Cost per patient database. At: https://stat2.skl.se/kpp/index.htm [accessed July 2011].
45. Danish Ministry for Health and Prevention. Ambulante DAGS takster efter høring. At: http://www.sum.dk/Sundhed/DRG-systemet/Takster.aspx [accessed September 2011].
46. T. Hujanen, S. Kapiainen, U. Tuominen, and M. Pekurinen Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006 2008 Stakes Työpapereita 3
47. Norwegian Directorate of Health ("Helsedirokteratet", personal contact November 2011).
48. The Southern Healthcare Region. Regional rates and allowances 2010. At: http://www.skane.se/ [accessed May 2011].
49. Expert opinion provided by working colleague of Leif Bjermer April 2011
50. GP's Association. Tariff for Danish GPs, as negotiated with Danish Regions ("Gruppe 2 takster") as of 1 October 2010. At: http://www.laeger.dk [accessed May 2011].
51. Norges Bank. Annual exchange rates. At: http://www.norges-bank.no/ [accessed June 2011].
52. Sveriges Riksbank. Yearly average exchange rates. At: http://www.riksbank.com/ [accessed May 2011].
53. Danmarks Nationalbank. Annual average exchange rates. At: http://www.nationalbanken.dk/ [accessed June 2011].
54. S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, and R. Goldstein Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial Ann Intern Med 146 2007 545 555
55. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
56. P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease Am J Respir Crit Care Med 175 2007 144 149
57. National Clinical Guideline Centre. Chronic Obstructive Pulmonary Disease: Management of adults with chronic obstructive pulmonary disease in primary and secondary care. National Institute for health and Clinical Excellence 2009. At: http://www.nice.org.uk/nicemedia/pdf/ COPDDraftConsultationGuideline.pdf [accessed May 2011].
58. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
59. J. Vestbo TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol Eur Respir J 24 2004 206 210
60. M.J. Fletcher, J. Upton, J. Taylor-Fishwick, S.A. Buist, C. Jenkins, and J. Hutton COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population BMC Public Health 11 2011 612
61. R. Nielsen, A. Johannessen, E.R. Omenaas, P.S. Bakke, J.E. Askildsen, and A. Gulsvik Excessive costs of COPD in ever-smokers. A longitudinal community study Respir Med 105 2011 485 493